These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34661166)

  • 41. Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg
    Al-Shuaeeb RAA; Abd El-Mageed HR; Ahmed SA; Mohamed HS; Hamza ZS; Rafi MO; Rahman MS
    J Biomol Struct Dyn; 2023; 41(21):11437-11449. PubMed ID: 36591698
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Delay induced stability switch in a mathematical model of CD8 T-cell response to SARS-CoV-2 mediated by receptor ACE2.
    Lv J; Ma W
    Chaos; 2024 Apr; 34(4):. PubMed ID: 38608314
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Global dynamics of IAV/SARS-CoV-2 coinfection model with eclipse phase and antibody immunity.
    Elaiw AM; Alsulami RS; Hobiny AD
    Math Biosci Eng; 2023 Jan; 20(2):3873-3917. PubMed ID: 36899609
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Viral and antibody dynamics of acute infection with SARS-CoV-2 omicron variant (B.1.1.529): a prospective cohort study from Shenzhen, China.
    Yang Y; Guo L; Yuan J; Xu Z; Gu Y; Zhang J; Guan Y; Liang J; Lu H; Liu Y
    Lancet Microbe; 2023 Aug; 4(8):e632-e641. PubMed ID: 37459867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SARS-CoV-2 viral dynamics in non-human primates.
    Gonçalves A; Maisonnasse P; Donati F; Albert M; Behillil S; Contreras V; Naninck T; Marlin R; Solas C; Pizzorno A; Lemaitre J; Kahlaoui N; Terrier O; Ho Tsong Fang R; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Rosa Calatrava M; de Lamballerie X; Mentré F; Le Grand R; van der Werf S; Guedj J
    PLoS Comput Biol; 2021 Mar; 17(3):e1008785. PubMed ID: 33730053
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Compartmental Model Suggests Importance of Innate Immune Response to COVID-19 Infection in Rhesus Macaques.
    Mochan E; Sego TJ; Gaona L; Rial E; Ermentrout GB
    Bull Math Biol; 2021 May; 83(7):79. PubMed ID: 34037874
    [TBL] [Abstract][Full Text] [Related]  

  • 47. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
    Yang W; Shaman J
    medRxiv; 2021 Nov; ():. PubMed ID: 34845460
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection.
    Totura AL; Whitmore A; Agnihothram S; Schäfer A; Katze MG; Heise MT; Baric RS
    mBio; 2015 May; 6(3):e00638-15. PubMed ID: 26015500
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diminished antiviral innate immune gene expression in the placenta following a maternal SARS-CoV-2 infection.
    Coler B; Wu TY; Carlson L; Burd N; Munson J; Dacanay M; Cervantes O; Esplin S; Kapur RP; Feltovich H; Adams Waldorf KM
    Am J Obstet Gynecol; 2023 Apr; 228(4):463.e1-463.e20. PubMed ID: 36126729
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improved SARS-CoV-2 sequencing surveillance allows the identification of new variants and signatures in infected patients.
    Grimaldi A; Panariello F; Annunziata P; Giuliano T; Daniele M; Pierri B; Colantuono C; Salvi M; Bouché V; Manfredi A; Cuomo MC; Di Concilio D; Tiberio C; Fiorenza M; Portella G; Cimmino I; Sorrentino A; Fusco G; Granata MR; Cerino P; Limone A; Atripaldi L; Ballabio A; Cacchiarelli D
    Genome Med; 2022 Aug; 14(1):90. PubMed ID: 35962405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Global dynamics of SARS-CoV-2/cancer model with immune responses.
    Elaiw AM; Al Agha AD
    Appl Math Comput; 2021 Nov; 408():126364. PubMed ID: 34002102
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: Insights into molecular mechanisms.
    Dinda B; Dinda M; Dinda S; De UC
    Eur J Med Chem; 2023 Oct; 258():115629. PubMed ID: 37437351
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A mathematical model for the dynamics of SARS-CoV-2 virus using the Caputo-Fabrizio operator.
    Khan T; Ullah R; Zaman G; Alzabut J
    Math Biosci Eng; 2021 Jul; 18(5):6095-6116. PubMed ID: 34517525
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.
    Lieber CM; Kang H-J; Sobolik EB; Sticher ZM; Ngo VL; Gewirtz AT; Kolykhalov AA; Natchus MG; Greninger AL; Suthar MS; Plemper RK
    J Virol; 2024 Sep; 98(9):e0090524. PubMed ID: 39207133
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mathematical modeling of intervention and low medical resource availability with delays: Applications to COVID-19 outbreaks in Spain and Italy.
    Bugalia S; Tripathi JP; Wang H
    Math Biosci Eng; 2021 Jun; 18(5):5865-5920. PubMed ID: 34517515
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human Nasal Epithelial Cells Sustain Persistent SARS-CoV-2 Infection
    Gamage AM; Tan KS; Chan WOY; Lew ZZR; Liu J; Tan CW; Rajagopalan D; Lin QXX; Tan LM; Venkatesh PN; Ong YK; Thong M; Lin RTP; Prabhakar S; Wang Y; Wang LF
    mBio; 2022 Feb; 13(1):e0343621. PubMed ID: 35038898
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A fractional-order differential equation model of COVID-19 infection of epithelial cells.
    Chatterjee AN; Ahmad B
    Chaos Solitons Fractals; 2021 Jun; 147():110952. PubMed ID: 33967407
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.